Anup Malani

Apr 28, 2024 | biorxiv.org | Stacy Rosenbaum |Anup Malani |Amanda Lea |Jenny Tung

AbstractIn evolutionary ecology, two classes of explanations are frequently invoked to explain "early life effects" on adult outcomes. Developmental constraints (DC) explanations contend that costs of early adversity arise from limitations adversity places on optimal development.

Apr 28, 2024 | biorxiv.org | Stacy Rosenbaum |Anup Malani |Amanda Lea |Jenny Tung

AbstractIn evolutionary ecology, two classes of explanations are frequently invoked to explain "early life effects" on adult outcomes. Developmental constraints (DC) explanations contend that costs of early adversity arise from limitations adversity places on optimal development.

Mar 1, 2024 | nature.com | Anup Malani

Correction to: Scientific Reports https://doi.org/10.1038/s41598-023-50338-3, published online 24 January 2024In the original version of this article, Vaidehi Tandel was incorrectly affiliated with Henley Business School, University of Reading, Reading, UK. The correct affiliation is as follows:University of Manchester, Manchester, UK. The original article has been corrected.

May 4, 2023 | healthaffairs.org | Jason Shafrin |Darius Lakdawalla |Jalpa A. Doshi |Louis P. Garrison |Anup Malani |Peter J. Neumann | +3 more

Medicare drug price negotiation is almost upon us. The Inflation Reduction Act (IRA) mandates that the Centers for Medicare and Medicaid Services (CMS) implement a maximum fair price (MFP) for drug price negotiation beginning in 2026. How should CMS implement such a program given such a short timeline? We recommend a three-step approach to implementing the MFP that moves toward a drug pricing paradigm based on treatment value.